Skip to main content

Thank you for visiting You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.


Microbiome therapeutics and patent protection

Obtaining patent protection for microbiome therapeutics has been affected profoundly by the US Supreme Court decisions in Myriad and Mayo, which redefined the scope of which natural phenomena, including microbiome therapeutics, are patent eligible.

Access options

Rent or Buy article

Get time limited or full article access on ReadCube.


All prices are NET prices.

Fig. 1
Fig. 2


  1. 1.

    Young, V. B. Br. Med. J. 356, j831 (2017).

    Article  Google Scholar 

  2. 2.

    Marchesi, J. R. et al. Gut 65, 330–339 (2016).

    Article  Google Scholar 

  3. 3.

    Brody, J. E. Unlocking the secrets of the microbiome. The New York Times (7 November 2017).

  4. 4.

    Anonymous. The human microbiome: me, myself, us. The Economist (18 August 2012).

  5. 5.

    Zhang, F., Luo, W., Shi, Y., Fan, Z. & Ji, G. Am. J. Gastroenterol. 107, 1755 (2012). author reply 1755–1756.

    Article  Google Scholar 

  6. 6.

    Borody, T. J. & Campbell, J. Expert Rev. Gastroenterol. Hepatol. 5, 653–655 (2011).

    Article  Google Scholar 

  7. 7.

    van Nood, E. et al. N. Engl. J. Med. 368, 407–415 (2013).

    Article  Google Scholar 

  8. 8.

    Atarashi, K. et al. Science 331, 337–341 (2011).

    CAS  Article  Google Scholar 

  9. 9.

    Tanoue, T. et al. Nature 565, 600–605 (2019).

    CAS  Article  Google Scholar 

  10. 10.

    Almeida, A. et al. Nature 568, 499–504 (2019).

    CAS  Article  Google Scholar 

  11. 11.

    DeFilipp, Z. et al. N. Engl. J. Med. 381, 2043–2050 (2019).

    Article  Google Scholar 

  12. 12.

    35 USC § 112(a).

  13. 13.

    Funk Brothers Seed Co. v. Kalo Inoculant Co., 333 US 127 (1948).

  14. 14.

    Diamond v. Chakrabarty, 447 US 303 (1980).

  15. 15.

    Mayo Collaborative Services v. Prometheus Laboratories, Inc., 566 US 66 (2012).

  16. 16.

    Association for Molecular Pathology v. Myriad Genetics, Inc., 569 US 576 (2013).

  17. 17.

    USPTO. Interim Guidance on Patent Subject Matter Eligibility, 79 FR 74618 (16 December 2014).

  18. 18.

    PTAB Case Number PGR2019-00002 (2019).

Download references

Author information



Corresponding author

Correspondence to Erik J. Spek.

Ethics declarations

Competing interests

M.J.F. is a partner in the intellectual property group at Nixon Peabody LLP. E.J.S. is an employee of Vedanta Biosciences, Inc., a company developing therapies for diseases based on human microbiome-derived bacteria.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

FitzGerald, M.J., Spek, E.J. Microbiome therapeutics and patent protection. Nat Biotechnol 38, 806–810 (2020).

Download citation

Further reading


Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing